J&J: Janssen seeking expanded use for leukaemia drug
(CercleFinance.com) - Johnson & Johnson's Janssen said that it has submitted an application to the European Medicines Agency seeking to expand the label of Imbruvica for the first-line treatment of patients with chronic lymphocytic leukaemia.
The submission is supported by data from a Phase 3 study that evaluated 529 patients and that demonstrated that the drug has shown superior progression-free survival and overall survival versus chemotherapy-based standard of care.
Imbruvica blocks the BTK protein, helping move abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The submission is supported by data from a Phase 3 study that evaluated 529 patients and that demonstrated that the drug has shown superior progression-free survival and overall survival versus chemotherapy-based standard of care.
Imbruvica blocks the BTK protein, helping move abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs.
Copyright (c) 2020 CercleFinance.com. All rights reserved.